Group 1 - The supervisory board of Jiangyin Hengrun Heavy Industry Co., Ltd. held its ninth meeting of the fifth session on August 22, 2025, to review various proposals [1][2] - The 2025 semi-annual report and its summary were found to comply with legal regulations and accurately reflect the company's operational and financial status without any false statements or omissions [1] - The provision and reversal of asset impairment for the first half of 2025 were deemed compliant with accounting standards, ensuring a fair representation of the company's financial condition and operational results [1] Group 2 - The company and its subsidiaries applied for additional credit from financial institutions and provided guarantees for loans within the credit limit to support operational and business development needs [2] - The financial status of the wholly-owned subsidiary Hengrun Ring Forging is stable, and its creditworthiness is good, with the company maintaining control over the guarantor's credit status [2] - The risks associated with the guarantees are considered manageable and do not harm the interests of the company or minority shareholders [2]

Summary of Key Points Core Viewpoint - The company, BrightGene (Suzhou) Pharmaceutical Co., Ltd., plans to apply for a comprehensive credit limit of up to 3 billion RMB for the year 2025 from banks and financial leasing companies, with mutual guarantees among its subsidiaries [1][2]. Group 1: Credit Application and Guarantee - The total credit limit proposed for 2025 is not to exceed 3 billion RMB, which will include various types of loans and financial services [1][2]. - As of December 31, 2024, the total amount of guarantees provided by the company to its subsidiaries is 1,139.63 million RMB, accounting for 47.59% of the company's audited net assets and 22.07% of its total audited assets for the year 2024 [1][20]. - The proposed guarantees do not involve any counter-guarantees [1]. Group 2: Shareholder Meeting and Authorization - The proposal for the credit application and guarantees will be submitted for approval at the company's 2024 annual general meeting [2]. - The shareholders will authorize the legal representative or their delegate to negotiate specific credit business types, terms, rates, and to sign relevant contracts and agreements [2]. Group 3: Subsidiary Information - BrightGene (Suzhou) Pharmaceutical Co., Ltd. holds an 80% stake in BrightGene Pharmaceutical (Suzhou) Co., Ltd., which has total assets of 571.92 million RMB and net assets of 277.19 million RMB as of December 31, 2023 [2][3]. - The company also has several subsidiaries, including Suzhou Guangtai Biotechnology Co., Ltd. and BrightGene International (HK) Limited, with varying financial metrics and operational scopes [3][4][5]. Group 4: Financial Health and Performance - The financial performance of the subsidiaries shows a mix of revenues and losses, with some subsidiaries reporting zero revenue and negative net profits for 2023 and projected for 2024 [3][4][5][10][11]. - The overall financial health of the company and its subsidiaries indicates a need for the proposed credit to support ongoing operations and growth [1][20]. Group 5: Board and Regulatory Approval - The board of directors approved the proposal with a unanimous vote, indicating strong internal support for the credit application and guarantee strategy [20]. - The proposal complies with relevant regulations and has undergone necessary approval processes as per the Shanghai Stock Exchange rules [20].